Bio-Rad Laboratories, Inc. Forecasted to Earn Q1 2025 Earnings of $2.39 Per Share (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Monday, April 15th. Zacks Research analyst R. Anand now anticipates that the medical research company will earn $2.39 per share for the quarter, up from their previous forecast of $2.35. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $3.83 EPS.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. During the same period in the prior year, the company posted $3.31 EPS. The firm’s quarterly revenue was down 6.7% compared to the same quarter last year.

A number of other brokerages have also weighed in on BIO. Royal Bank of Canada cut their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Finally, UBS Group upped their target price on Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $468.00.

Bio-Rad Laboratories Trading Down 3.4 %

Shares of NYSE:BIO opened at $281.02 on Wednesday. The business’s 50-day moving average is $330.76 and its 200 day moving average is $320.72. Bio-Rad Laboratories has a 1 year low of $261.59 and a 1 year high of $489.36. The firm has a market capitalization of $8.01 billion, a P/E ratio of -13.08 and a beta of 0.87. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new position in shares of Bio-Rad Laboratories during the fourth quarter worth $27,000. Farther Finance Advisors LLC increased its position in shares of Bio-Rad Laboratories by 42.3% during the second quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock worth $38,000 after purchasing an additional 30 shares in the last quarter. Sound Income Strategies LLC acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at about $38,000. Gladius Capital Management LP increased its position in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 48 shares during the period. Finally, Principal Securities Inc. purchased a new stake in Bio-Rad Laboratories in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the transaction, the executive vice president now owns 6,942 shares of the company’s stock, valued at $2,332,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.